flutamide and goserelin

flutamide has been researched along with goserelin in 193 studies

Research

Studies (193)

TimeframeStudies, this research(%)All Research%
pre-19907 (3.63)18.7374
1990's94 (48.70)18.2507
2000's64 (33.16)29.6817
2010's27 (13.99)24.3611
2020's1 (0.52)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jorion, JL1
Haefliger, JM1
Huben, RP1
Schmeller, N1
Armitage, TG; Cooper, EH; Denis, L; Newling, DW; Richards, BR; Robinson, MR; Smith, PH; Sylvester, R1
Bono, A; Carneiro de Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R1
Baldelli, S; Cellerino, R; Menichetti, ET; Miseria, S; Murer, B; Torresi, U; Tummarello, D1
Fischer, M; Flamm, J; Höltl, W; Pflüger, H; Tomschi, W1
Altwein, JE; Boccardo, F; Haefliger, JM; Holdaway, IM; Jordaan, JP; Klippel, F; Lunglmayr, G; Tyrrell, CJ; Varenhorst, E1
Horlbeck, R; Jurincic, CD; Klippel, KF1
Berná, L; Blanco, R; Carrió, I; Estorch, M; Germá, JR; Torres, G1
Denis, L3
Ayub, M; Levell, MJ1
Armitage, TG; Bono, A; Calais da Silva, F; Debruyne, F; Denis, L; Robinson, P; Smith, PH; Sylvester, R1
De Pauw, M; Denis, L; Newling, DW; Robinson, MR; Sylvester, R1
Christensen, I; Denis, L; Iversen, P; Suciu, S; Sylvester, R2
Bond, A; Carvalho, AP; De Pauw, M; Denis, L; Keuppens, F; Newling, D; Ongena, P; Smith, P; Sylvester, R; Vermeylen, K1
Christensen, MG; Friis, E; Hornbøl, P; Hvidt, V; Iversen, HG; Iversen, P; Klarskov, P; Krarup, T; Lund, F; Mogensen, P1
Schulze, H; Senge, T1
Bono, A; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Pinto de Carvalho, AP; Robinson, M; Smith, P; Sylvester, R1
D'Eramo, G; Di Silverio, F; Sciarra, F1
Hwang, YS; John, MJ; Krall, JM; McGowan, D; Perez, CA; Pilepich, MV1
Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R1
Guidez, C1
Lunglmayr, G2
Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, DW; Robinson, M; Smith, PH; Sylvester, R1
Iversen, P1
Cariou, G; Coloby, P; Colombel, P; Coulange, C; Fourcade, RO; Grise, P; Mangin, P; Poterre, M; Soret, JY1
Boccardo, F; Cortellini, P; Decensi, A; Delli Ponti, U; Giuliani, L; Guarneri, D; Martorana, G; Oneto, F; Petracco, S; Rubagotti, A1
Bono, A; Carvalho, AP; de Moura, JL; De Pauw, M; Denis, L; Newling, D; Ongena, P; Smith, P; Sylvester, R1
Ceda, GP; Ceresini, G; Cortellini, P; Denti, L; Hoffman, AR; Valenti, G1
Aaronson, N; Da Silva, FC1
Kaldenhoff, H; Schulze, H; Senge, T1
Bouffioux, C1
Derde, MP; Kaufman, L; Mattelaer, J; Oosterlinck, W1
Abellera, M; Chen, GT; Chiru, P; Hamilton, RJ; Ray, P; Spelbring, D; Vaida, F; Vijayakumar, S; Yang, FE1
Cespedes, RD; Jackson, C; Peretsman, SJ; Thompson, IM1
Crawford, ED1
Mottrie, AM; Müller, SC; Stöckle, M; Voges, GE1
Schulman, CC1
Aprikian, AG; Armas, OA; Cohen, DW; Cordon-Cardo, C; Erlandson, R; Fair, WR; Melamed, J; Reuter, VE1
Cheson, BD; Kaplan, RS; Phillips, PH1
Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N2
Brogden, RN; Faulds, D1
Huhtaniemi, I; Kangasniemi, M; Meistrich, ML; Wilson, G1
Abrams, RA; al-Sarraf, M; Doggett, RL; John, MJ; Krall, JM; Lawton, CA; Pilepich, MV; Rotman, M; Rubin, P; Sause, WT1
Debruyne, FM; Oosterhof, GO; Schulman, CC; van Cangh, PJ; Witjes, WP1
Labrie, F1
Begbie, SD; Bell, DR; Blome, SA; Stevens, MJ1
Bottero, G; Buffa, G; Ferraris, V; Novella, V; Pacilli, N; Pisano, PF1
Aprikian, AG; Cohen, D; Fair, WR; Reuter, V; Sogani, P1
Dorr, RP; Lee, F; McHugh, TA; Siders, DB; Solomon, MH1
Buffa, G; Ferraris, V; Pacilli, N; Pisano, PF1
Denis, L; Newling, DW; Vermeylen, K1
Christensen, IJ; Iversen, P; Klarskov, P; Rasmussen, F1
Bono, A; Carneiro de Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Sylvester, R; Whelan, P1
Altwein, JE; Boccardo, F; Haefliger, JM; Holdaway, IM; Jordaan, JP; Klippel, F; Lunglmayr, G; Sotarauta, M; Tyrrell, CJ; Varenhorst, E1
da Silva, FC1
Heathcote, PS; Kateley, GD; Lloyd, S; Nicol, DL1
Bono, A; Carnelro de Moura, JL; Denis, LJ; Depauw, M; Newling, D; Sylvester, R; Whelan, P1
Waxman, J1
Battaglia, M; Boccardo, F; Decensi, A; Giuliani, L; Guarneri, D; Martorana, G; Oneto, F; Pace, M; Rubagotti, A; Selvaggi, F1
Fichtner, J; Hohenfellner, R; Mappes, C; Mottrie, AM; Stöckle, M; Störkel, S; Voges, GE1
Aridogan, IA; Yachia, D1
Andras, EJ; Brooks, CP; Chang, GC; Gilbert, RM; Leibenhaut, MH; Linstadt, DE; Rosenthal, SA; Stickney, DR; Wolkov, HB1
Aaronson, NK; Casselman, J; da Silva, FC; Denis, L; Fava, C; Fossa, SD; Hetherington, J; Richards, B; Robinson, MR; Serbouti, S; Whelan, P1
Ablondi, F; Cortellini, P; Denti, L; Ferretti, S; Pasolini, G; Sanfelici, L; Valenti, G1
Scalliet, P1
Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, MS; Venner, P; Vogelzang, N1
Acar, O; Goldschmidt, AJ; Tunn, UW1
Ago, CT; Asbell, SO; Brereton, HD; Leon, SA; Rotman, M; Tester, WJ1
Block, NL; Chen, Y; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ1
Abrams, RA; Caplan, R; Cox, JD; Forman, JD; Fu, KK; Grignon, DJ; Hammond, EH; Lawton, CA; Mesic, J; Pajak, TF; Pilepich, MV; Sarkar, FH; Shipley, WU1
Begg, CB; Cookson, MS; Dalbagni, G; Fair, WR; Herr, H; Reuter, VE; Russo, P; Sheinfeld, J; Sogani, PC1
Aprikian, AG; Begg, CB; Cohen, D; Cookson, MS; Dalgabni, G; Fair, WR; Herr, H; Heston, WD; Reuter, VE; Russo, P; Sheinfeld, J; Sogani, P; Soloway, SM; Stroumbakis, N; Wang, Y1
Debruyne, FM; Schulman, CC; Witjes, WP1
Akaza, H; Aso, Y; Isaka, S; Kanetake, H; Koiso, K; Kotake, T; Usami, M1
Block, NL; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ1
Anderson, PR; Hanks, GE; Hanlon, AL; Movsas, B1
de Voogt, H; Denis, L; Sylvester, RJ1
Bono, A; de Moura, JL; Denis, LJ; Keuppens, F; Newling, D; Smith, PH; Sylvester, R; Whelan, P1
Block, NL; Chodak, GW; Klein, EA; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ1
Chatelain, C; Fourcade, RO1
Hirao, Y; Ozono, S1
Bryant, C; Campbell, J; Diamond, T; Lynch, W1
Cole, BF; Curran, D; Denis, LJ; Hall, RR; Kiebert, GM; Rosendahl, I; Weeks, JC1
Collinson, MP; Daniel, F; Teasdale, C; Tyrrell, CJ1
Altinbaş, M; Cetin, M; Demirci, D; Güven, M; Unal, A; Unlühizarci, K1
Altwein, J; Boyle, P; Denis, LJ; Griffiths, K; Kirby, R; Robertson, C; Schröder, F; Turkes, A1
Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ1
Higashi, T; Maruyama, Y; Nagayoshi, J1
Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G1
Carroll, K; Johnson, R; Kolvenbag, GJ; Sarosdy, MF; Schellhammer, PF1
Altwein, JE; Boccardo, F; Haefliger, JM; Holdaway, IM; Jordaan, JP; Jurincic-Winkler, C; Klippel, F; Lunglmayr, G; Tyrrell, CJ; Varenhorst, E1
Halachmi, S; Madeb, R; Madjar, S; Nativ, O; River, Y; Wald, M1
Denham, J; Franklin, I; Joseph, D; Kovacev, O; Lamb, D; Mameghan, H; Matthews, J; North, J; Poulsen, M; Spry, N; Steigler, A; Turner, S1
Baba, S; Egawa, S; Kuwao, S; Matsumoto, K; Mizoguchi, H; Takashima, R1
Aizawa, Y; Ikemoto, I; Ohishi, Y; Wada, T; Yamazaki, H1
Betancourt, JE; Fair, WR1
Debruyne, FM; Witjes, WP1
Debruyne, FM; Forster, G; Schulman, CC; Selvaggi, FP; Witjes, WP; Zlotta, AR1
Fukunaga, M; Jo, Y; Sone, T; Tamada, T; Tanaka, H; Tomomitsu, T1
Aoyagi, T; Hata, M; Hayakawa, K; Matsumoto, M; Miyaji, K1
Bechev, R; Chakarov, S; Fachikov, Ts; Lazarov, Z; Rangelov, S1
Bryc, W; Kokot, F; Nowicki, M1
Hashimoto, H; Inada, F; Ishida, H; Kawakami, N; Kitahara, K; Masui, N; Saga, Y; Tokumitsu, M; Yachiku, S1
Leibowitz, RL; Tucker, SJ1
Mazeron, JJ; Noël, G1
Collette, L; Denis, LJ; Schröder, FH; Studer, UE; Sylvester, RJ1
Grignon, D; John, MJ; Lawton, C; Machtay, M; Mesic, JB; Pilepich, MV; Rubin, P; Sause, W; Winter, K1
Fukuoka, H; Harada, M; Hosaka, M; Kitami, K; Miura, T; Moriyama, M; Noguchi, K; Uemura, H1
Bryant, C; De Souza, P; Diamond, TH; Kersley, JH; Lynch, WJ; Smith, A; Winters, J1
Plöen, L; Ritzen, EM; Setchell, BP1
Candas, B; Cusan, L; Gomez, JL; Labrie, F1
Fukuda, M; Fuse, H; Hirano, S; Takashima, H1
Carroll, PR; Crawford, ED; DeVERE WHITE, R; Haas, G; Lowe, BA; Miller, GJ; Osswald, MB; Powell, IJ; Tangen, CM; Thompson, IM1
Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Cortellini, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rigatti, P; Rubagotti, A; Usai, E1
Akay, AF; Bircan, MK; Deniz, M; Göçmen, M; Nergiz, Y; Sahin, H1
Heydon, K; Lawton, CA; Lu, JD; Machtay, M; Pilepich, MV; Roach, M; Rubin, P; Sause, WT; Shipley, WU; Wolkov, HB1
Asbell, SO; Grignon, D; Lu, J; Mohiuddin, M; Pilepich, MV; Roach, M1
Mizokami, A; Namiki, M1
Duncan, WE; Harding, P; Howard, RS; McLeod, DG; Preston, DM; Torréns, JI1
Agarwal, S; Bulpitt, CJ; Dockery, F; Rajkumar, C1
Abrams, RA; Fu, KK; Grignon, DJ; Hammond, EH; Heydon, KH; Lawton, CA; Mesic, JB; Pollack, A; Porter, AT; Shipley, WU1
Igaki, H; Kaizu, T; Karasawa, K; Matsuda, T; Niibe, Y; Shinohara, M; Tanaka, Y1
Abdalla, I; Basu, A; Connell, PP; Jani, AB; Krauz, L; Vijayakumar, S1
Atkinson, C; Christie, D; Denham, JW; Duchesne, G; Francis, L; Franklin, I; Joseph, D; Kovacev, O; Lamb, DS; Mameghan, H; Matthews, J; North, J; Poulsen, M; Robertson, R; Spry, NA; Tai, KH; Turner, S; Wynne, C1
Budde, A; Caprano, J; Helpap, B; Hopfenmüller, W; Köllermann, J; Weidenfeld, H; Weidenfeld, M1
Gerald, WL; Holzbeierlein, J; Lal, P; LaTulippe, E; Reuter, V; Ryan, C; Satagopan, J; Scardino, P; Scher, H; Smith, A; Smith, S; Zhang, L1
Choudhury, AM; Tanvetyanon, T1
Andrianne, R; Boca, P; Bonnet, P; Bouffioux, C; Coppens, L; de Leval, J; Jeukenne, M; Nicolas, H; Seidel, L; Wlatregny, D; Yousef, E1
Aslan, P; Bryant, C; Bucci, J; Diamond, TH; Kersley, JH; Lynch, WB1
D'Amico, AV; DellaCroce, A; Kantoff, PW; Loffredo, M; Manola, J; Renshaw, AA1
Bowen, J; Crook, J; Eapen, L; Lim, J; Lockwood, G; Ludgate, C; Malone, S; Perry, G; Robertson, S1
Miyakita, H1
Gratzle, J; Jani, AB; Myers, M1
Gratzle, J; Jani, AB1
Atkinson, C; Christie, D; D'Este, C; Denham, JW; Duchesne, G; Franklin, I; Joseph, D; Kovacev, O; Lamb, DS; Mameghan, H; Matthews, J; North, J; Poulsen, M; Spry, NA; Steigler, A; Tai, KH; Turner, S; Wynne, C1
Brereton, H; Feigenberg, S; Hanks, G; Konski, A; Watkins-Bruner, D1
Desilvio, M; Lawton, CA; Pilepich, MV; Roach, M; Rubin, P; Sause, WT; Shipley, WU; Wolkov, HB1
Fujisawa, M; Hara, I; Inoue, TA; Miyake, H; Sakai, I1
Gerald, W; Lal, P; Reuter, V; Ryan, CJ; Satagopan, J; Scardino, P; Scher, HI; Smith, A1
Arichi, N; Ichikawa, Y; Kishikawa, H; Nishimura, K; Tokugawa, S; Yoshioka, I1
De Silvio, M; Fisher, B; Grignon, D; Hanks, G; Pollack, A; Rebbick, T; Roach, M; Rotman, M; Sandler, H; Shipley, WU; Watkins-Bruner, D; Wolkov, H1
Hashimoto, Y; Ikarashi, T; Nishiyama, T; Takahashi, K; Wako, K1
Bae, K; Hanks, G; Lawton, CA; Pilepich, M; Shipley, W1
Bae, K; Grignon, D; Lawton, C; Lee, RJ; Pilepich, MV; Roach, M; Rubin, P; Speight, J; Valicenti, R; Wolkov, HB1
Bae, K; Efstathiou, JA; Hanks, GE; Pilepich, MV; Sandler, HM; Shipley, WU; Smith, MR1
Whelan, P1
Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, B; Renshaw, AA1
Bowen, J; Crook, J; Eapen, L; Lockwood, G; Ludgate, C; Malone, S; Perry, G; Robertson, S1
Kempkensteffen, C; Kleinschmidt, K; Köllermann, J; Pantel, K; Rau, T; Schostak, M; Weikert, S1
Gao, X; Lu, X; Sun, YH; Tang, YJ; Zhou, T1
Crook, JM; Eapen, L; Fung, S; Lockwood, G; Ludgate, C; Malone, S; Owen, J; Perry, G; Robertson, S1
Bae, K; Hanks, GE; Hussain, MH; Ray, ME; Sandler, HM; Shipley, WU1
Burri, RJ; Cesaretti, JA; Ho, AY; Stock, RG; Stone, NN1
Alexander, A; Bowen, J; Crook, J; Jones, S; Ludgate, C; Malone, S; Pai, H; Truong, P1
Cronin, AM; Eastham, JA; Lowrance, WT; Maschino, AC; Rabbani, F; Yee, DS1
Hara, N; Hoshii, T; Isahaya, E; Nishiyama, T; Takahashi, K; Takizawa, I3
Antczak, A; Baczyk, M; Kwias, Z; Martenka, P; Milecki, P; Skowronek, J1
Bjartell, A; Dahlman, A; Edsjö, A; Fine, SW; Gerald, W; Halldén, C; Lilja, H; Persson, JL1
Atkinson, C; Christie, D; D'Este, C; Denham, JW; Joseph, D; Lamb, DS; Matthews, J; North, J; Spry, NA; Steigler, A; Tai, KH; Turner, S; Wynne, C1
Hara, N; Hoshii, T; Isahaya, E; Ishizaki, F; Nishiyama, T; Takahashi, K; Takizawa, I1
Kobayashi, M; Kurokawa, S; Morita, T; Nukui, A; Suzuki, K1
Amin, MB; Bruner, DW; Chetner, MP; Hunt, D; Husain, SM; Jones, CU; Leibenhaut, MH; McGowan, DG; Rotman, M; Sandler, HM; Shipley, WU; Souhami, L1
Bhinder, A; Clinton, SK; Friedman, A; Jain, HV1
Berglund, RK; Canby-Hagino, ED; Carroll, PR; Crawford, ED; deVere White, R; Haas, GP; Hemstreet, GP; Klein, EA; Lowe, BA; Powell, IJ; Tangen, CM; Thompson, IM1
Both, S; Guzzo, TJ; Haas, NB; Hwang, WT; Jang, JW; Vapiwala, N; Wein, AJ1
Antes, G; Dahm, P; Grobe, HR; Kunath, F; Meerpohl, JJ; Motschall, E; Rücker, G; Wullich, B1
Amin, MB; Balogh, AG; Bauman, GS; Chinn, DM; Dignam, JJ; Duclos, M; Gomella, LG; Gore, EM; Hunt, D; Lukka, HR; Pisansky, TM; Rosenthal, SA; Rotman, MZ; Sandler, HM; Seider, MJ; Shipley, WU1
Bristow, RG; Dal Pra, A; Locke, JA; Supiot, S; Warde, P1
Bahary, JP; Chafe, S; Efstathiou, JA; Gore, E; Husain, SM; Jones, CU; Leibenhaut, MH; McGowan, DG; Paulus, R; Raben, A; Rotman, M; Sandler, HM; Shipley, WU; Smith, MR; Souhami, L; Voog, JC; Zeitzer, KL1
Ding, K; He, W; Liu, S; Wu, H; Zhang, T1
Bedi, M; Brereton, HD; Dignam, JJ; Grignon, DJ; Hanks, GE; Horwitz, EM; Kim, H; Kwok, Y; Lawton, CAF; Lepor, H; Lin, X; Parliament, MB; Pisansky, TM; Rabinovitch, R; Roach, M; Rosenthal, SA; Sandler, HM; Venkatesan, VM; Zeitzer, KL1
Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X1
García-Perdomo, HA; Reis, LO; Zani, EL1
Abdullaev, NA; Bakarev, MA; Kachesov, IV; Levin, VP; Neimark, AI1
Dicker, AP; Gore, EM; Hartford, AC; Horwitz, EM; Hsu, IC; Jones, CU; Kim, HE; Kwok, Y; Lawton, CAF; Lee, WR; Michalski, JM; Moughan, J; Pisansky, TM; Pryzant, RM; Rabinovitch, R; Roach, M; Rotman, M; Sandler, HM; Seider, MJ; Shipley, WU; Thomas, CR; Yamoah, K; Zeitzer, KL1
Bryant, AK; Deka, R; McKay, R; Murphy, JD; Nalawade, V; Rose, BS; Sarkar, RR; Simpson, DR1
Chen, C; Li, J; Shen, P; Wu, B; Wu, F; Xu, T; Yin, X; Yu, L1

Reviews

16 review(s) available for flutamide and goserelin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
    Drugs & aging, 1995, Volume: 6, Issue:4

    Topics: Absorption; Aged; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Estrogens; Flutamide; Gonadotropins; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Steroids

1995
Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
    Clinical and investigative medicine. Medecine clinique et experimentale, 1993, Volume: 16, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Preoperative Care; Prostatectomy; Prostatic Neoplasms

1993
Role of maximal androgen blockade in advanced prostate cancer.
    The Prostate. Supplement, 1994, Volume: 5

    Topics: Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Analysis; Treatment Outcome

1994
Androgen deprivation for prostatic carcinoma: a rationale for choosing components.
    International journal of urology : official journal of the Japanese Urological Association, 1998, Volume: 5, Issue:4

    Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds

1998
[Total androgen blockade--concept, theory, method and clinical application].
    Nihon rinsho. Japanese journal of clinical medicine, 1998, Volume: 56, Issue:8

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms

1998
[Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2001, Volume: 47, Issue:1

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Lung Neoplasms; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Treatment Outcome

2001
[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2001, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Survival Analysis; Treatment Outcome

2001
[Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2002, Volume: 48, Issue:8

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Drug Administration Schedule; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lung Neoplasms; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Tomography, X-Ray Computed

2002
[Total androgen blockade].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 11

    Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Chlormadinone Acetate; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds

2002
Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
    International journal of radiation oncology, biology, physics, 2003, May-01, Volume: 56, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Chlormadinone Acetate; Diethylstilbestrol; Disease-Free Survival; Flutamide; Follow-Up Studies; Gastrointestinal Diseases; Goserelin; Humans; Imaging, Three-Dimensional; Japan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Rotation; Survival Analysis; Treatment Outcome; Urination Disorders

2003
[Hormonal therapy for prostatic cancer--state of the art].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63, Issue:2

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Diethylstilbestrol; Drug Therapy, Combination; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Meta-Analysis as Topic; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic

2005
First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire international, 2013, Volume: 22, Issue:135

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Cyproterone; Estrogens; Flutamide; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Practice Guidelines as Topic; Prostatic Neoplasms; Time Factors; Treatment Outcome

2013
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    The Cochrane database of systematic reviews, 2014, Jun-30, Issue:6

    Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Medication Adherence; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Triptorelin Pamoate

2014
Synergistic action of image-guided radiotherapy and androgen deprivation therapy.
    Nature reviews. Urology, 2015, Volume: 12, Issue:4

    Topics: Androgen Antagonists; Androstenes; Benzamides; Biomarkers; Combined Modality Therapy; Dose-Response Relationship, Radiation; Flutamide; Goserelin; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiotherapy, Image-Guided; Risk Assessment; Treatment Outcome

2015
Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
    International urology and nephrology, 2018, Volume: 50, Issue:6

    Topics: Anilides; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Estrogens, Non-Steroidal; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds

2018

Trials

102 trial(s) available for flutamide and goserelin

ArticleYear
[Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate].
    Helvetica chirurgica acta, 1992, Volume: 59, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Flutamide; Goserelin; Humans; Male; Neoplasm Recurrence, Local; Prostate; Prostatic Neoplasms

1992
Hormone therapy of prostatic bone metastases.
    Advances in experimental medicine and biology, 1992, Volume: 324

    Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbestrol; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Ketoconazole; Leuprolide; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Remission Induction; Spironolactone; Survival Rate

1992
[The role of LH-RH analogues in the treatment of prostate cancer. Report of a conference organized by ICI-Pharma laboratories (part 2)].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1991, Volume: 1, Issue:2

    Topics: Adenocarcinoma; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Orchiectomy; Patient Satisfaction; Prostatic Neoplasms; Survival Rate

1991
Total androgen ablation: European experience. The EORTC GU Group.
    The Urologic clinics of North America, 1991, Volume: 18, Issue:1

    Topics: Aged; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms

1991
Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate.
    European urology, 1991, Volume: 19, Issue:3

    Topics: Aged; Buserelin; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Pilot Projects; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Time Factors

1991
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    The Journal of urology, 1991, Volume: 146, Issue:5

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Delayed-Action Preparations; Drug Tolerance; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Remission Induction; Time Factors; United Kingdom

1991
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
    Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Remission Induction; Survival Rate

1991
Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Radionuclide Imaging; Randomized Controlled Trials as Topic; Survival Rate

1990
Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5 Suppl

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate

1990
Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5 Suppl

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Orchiectomy; Prognosis; Prostatic Neoplasms; Radionuclide Imaging; Randomized Controlled Trials as Topic; Survival Rate

1990
A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5 Suppl

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate

1990
Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate

1990
Complete androgen blockade: data from an EORTC 30853 trial.
    Seminars in urology, 1990, Volume: 8, Issue:3

    Topics: Aged; Anilides; Buserelin; Combined Modality Therapy; Europe; Flutamide; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate

1990
Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
    European urology, 1990, Volume: 18, Issue:1

    Topics: Aged; Androgen Antagonists; Anilides; Buserelin; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation

1990
Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy.
    American journal of clinical oncology, 1990, Volume: 13, Issue:6

    Topics: Buserelin; Diarrhea; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Radiotherapy

1990
Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
    The Journal of steroid biochemistry and molecular biology, 1990, Dec-20, Volume: 37, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Drug Combinations; Drug Evaluation; Europe; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Risk Factors

1990
[How can a nursing team participate in a clinical trial? Zoladex, flutamide trial].
    Soins; la revue de reference infirmiere, 1990, Issue:540

    Topics: Buserelin; Clinical Trials as Topic; Flutamide; Goserelin; Humans; Job Description; Male; Nursing Staff, Hospital; Prostatic Neoplasms

1990
A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    European urology, 1990, Volume: 18 Suppl 3

    Topics: Buserelin; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms

1990
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
    European urology, 1990, Volume: 18 Suppl 3

    Topics: Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Carcinoma; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Liver Function Tests; Male; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Survival Rate

1990
Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
    European urology, 1990, Volume: 18 Suppl 3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Survival Rate

1990
Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
    European urology, 1990, Volume: 18 Suppl 3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate

1990
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
    European urology, 1990, Volume: 18 Suppl 3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Survival Rate

1990
Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.
    Progress in clinical and biological research, 1989, Volume: 303

    Topics: Anilides; Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Random Allocation

1989
'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
    Progress in clinical and biological research, 1989, Volume: 303

    Topics: Aged; Anilides; Buserelin; Clinical Trials as Topic; Drug Therapy, Combination; Flutamide; Goserelin; Humans; International Cooperation; Male; Multicenter Studies as Topic; Prognosis; Prostatic Neoplasms; Random Allocation

1989
Quality of life assessment in prostatic cancer.
    Progress in clinical and biological research, 1988, Volume: 260

    Topics: Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires

1988
Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
    Urologia internationalis, 1988, Volume: 43, Issue:4

    Topics: Androgen Antagonists; Androgens; Buserelin; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Random Allocation

1988
Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
    European urology, 1988, Volume: 15, Issue:3-4

    Topics: Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Time Factors

1988
Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients.
    Acta urologica Belgica, 1995, Volume: 63, Issue:3

    Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Castration; Combined Modality Therapy; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Prostatic Neoplasms; Triptorelin Pamoate

1995
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.
    The American journal of surgical pathology, 1994, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Cell Division; Combined Modality Therapy; Diploidy; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms

1994
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
    Urology, 1995, Volume: 45, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Rate; Tosyl Compounds; Treatment Failure

1995
Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.
    Urology, 1995, Volume: 45, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms

1995
A phase III trial (RTOG 8610) comparing external-beam irradiation plus short-term maximal androgen blockade with radiation therapy alone for locally advanced prostate cancer. The Radiation Therapy Oncology Group.
    European urology, 1994, Volume: 26 Suppl 1

    Topics: Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Radiotherapy, High-Energy

1994
A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment.
    European urology, 1994, Volume: 26 Suppl 1

    Topics: Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms

1994
Prolonged hypogonadism after pulsed gonadotropin-releasing hormone agonist for prostate cancer.
    Lancet (London, England), 1994, Jul-23, Volume: 344, Issue:8917

    Topics: Combined Modality Therapy; Erectile Dysfunction; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testis; Testosterone

1994
[Treatment of prostatic carcinoma in clinical stage C. Comparison between radiotherapy plus hormonal therapy after progression and immediate hormonal therapy].
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 1994, Volume: 46, Issue:2

    Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Infant; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms

1994
Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
    Clinical and investigative medicine. Medecine clinique et experimentale, 1993, Volume: 16, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Preoperative Care; Prostatectomy; Prostatic Neoplasms

1993
Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy.
    Clinical and investigative medicine. Medecine clinique et experimentale, 1993, Volume: 16, Issue:6

    Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Preoperative Care; Prostatectomy; Prostatic Neoplasms

1993
Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.
    Cancer, 1993, Dec-15, Volume: 72, Issue:12 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Flutamide; Goserelin; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Orchiectomy; Prospective Studies; Prostatic Neoplasms

1993
Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer.
    Cancer, 1993, Dec-15, Volume: 72, Issue:12 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate

1993
Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group.
    Cancer, 1993, Dec-15, Volume: 72, Issue:12 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Survival Rate

1993
Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group.
    Cancer, 1993, Dec-15, Volume: 72, Issue:12 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Survival Rate

1993
Quality of life in prostatic carcinoma.
    European urology, 1993, Volume: 24 Suppl 2

    Topics: Activities of Daily Living; Flutamide; Goserelin; Humans; Interpersonal Relations; Male; Orchiectomy; Pain; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Surveys and Questionnaires; Urination Disorders

1993
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
    Urology, 1993, Volume: 42, Issue:2

    Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Analysis

1993
Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:8

    Topics: Acid Phosphatase; Aged; Aged, 80 and over; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Time Factors

1993
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Urology, 1996, Volume: 47, Issue:1A Suppl

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Tosyl Compounds

1996
The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Medical Staff, Hospital; Middle Aged; Orchiectomy; Patient Compliance; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires

1996
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    European urology, 1996, Volume: 29 Suppl 2

    Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug Synergism; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Tosyl Compounds

1996
Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
    Urologia internationalis, 1996, Volume: 56 Suppl 1

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors

1996
Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy.
    The Prostate, 1996, Volume: 29, Issue:4

    Topics: Aged; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Black People; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Goserelin; Hemoglobins; Humans; Male; Pelvis; Prostatic Neoplasms; Remission Induction; White People

1996
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
    Cancer, 1996, Nov-15, Volume: 78, Issue:10

    Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds

1996
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.
    British journal of urology, 1997, Volume: 79, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Goserelin; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Treatment Outcome

1997
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
    Urology, 1997, Volume: 49, Issue:3A Suppl

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Preoperative Care; Prostatic Neoplasms

1997
Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatmen
    Urology, 1997, Volume: 49, Issue:3A Suppl

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time Factors

1997
Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer.
    International journal of urology : official journal of the Japanese Urological Association, 1996, Volume: 3, Issue:6

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Diarrhea; Dose-Response Relationship, Drug; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms

1996
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Urology, 1997, Volume: 50, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds

1997
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    European urology, 1998, Volume: 33, Issue:2

    Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Combined Modality Therapy; Cyproterone Acetate; Disease-Free Survival; Flutamide; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Orchiectomy; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Survival Rate

1998
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
    European urology, 1998, Volume: 33, Issue:2

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Disease Progression; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome

1998
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Urology, 1998, Volume: 52, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds

1998
Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
    The Prostate, 1999, Feb-01, Volume: 38, Issue:2

    Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Neoplasm Metastasis; Orchiectomy; Pain Measurement; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Survival Analysis

1999
Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
    The Prostate, 1999, Jul-01, Volume: 40, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms

1999
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
    The Prostate, 1999, Sep-01, Volume: 40, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Black People; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; White People

1999
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Consumer Product Safety; Disease Progression; Disease-Free Survival; Erectile Dysfunction; Flutamide; Goserelin; Humans; Italy; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds

1999
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
    Urology, 2000, Volume: 55, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds

2000
Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
    European urology, 2000, Volume: 37, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Survival Rate

2000
A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
    Australasian radiology, 2000, Volume: 44, Issue:1

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Costs and Cost Analysis; Flutamide; Goserelin; Humans; Male; Medical Audit; Prostatic Neoplasms; Quality Assurance, Health Care; Radiotherapy, Adjuvant; Time Factors

2000
Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Molecular urology, 2000,Fall, Volume: 4, Issue:3

    Topics: Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Europe; Flutamide; Goserelin; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms

2000
4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.
    European urology, 2000, Volume: 38, Issue:6

    Topics: Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Disease-Free Survival; Europe; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Neoplasm Staging; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors

2000
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    The oncologist, 2001, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome

2001
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Life Tables; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prostatic Neoplasms; Radiotherapy, High-Energy; Survival Analysis; Treatment Outcome

2001
Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist.
    International journal of clinical oncology, 2001, Volume: 6, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Delayed-Action Preparations; Drug Administration Schedule; Flutamide; Goserelin; Humans; Injections, Subcutaneous; Leuprolide; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms

2001
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
    Cancer, 2001, Sep-15, Volume: 92, Issue:6

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density; Cross-Over Studies; Diphosphonates; Double-Blind Method; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Injections, Intravenous; Male; Osteoporosis; Pamidronate; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone

2001
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Urology, 2002, Volume: 60, Issue:1

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Longitudinal Studies; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Triptorelin Pamoate

2002
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
    European urology, 2002, Volume: 42, Issue:5

    Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Flutamide; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome

2002
Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
    International journal of radiation oncology, biology, physics, 2002, Dec-01, Volume: 54, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Recurrence; Salvage Therapy; Time Factors; Treatment Outcome

2002
Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
    The aging male : the official journal of the International Society for the Study of the Aging Male, 2002, Volume: 5, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Arteries; Cardiovascular Diseases; Flutamide; Goserelin; Hemodynamics; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Vascular Patency

2002
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Apr-01, Volume: 21, Issue:7

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Diploidy; DNA, Neoplasm; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate

2003
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2003, Volume: 68, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Erectile Dysfunction; Flutamide; Goserelin; Humans; Intestines; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder

2003
Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
    Clinical prostate cancer, 2002, Volume: 1, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Drug Administration Schedule; Flutamide; Goserelin; Humans; Injections, Subcutaneous; Male; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms

2002
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Survival Analysis

2004
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    International journal of radiation oncology, biology, physics, 2004, Sep-01, Volume: 60, Issue:1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatic Neoplasms; Statistics, Nonparametric; Survival Rate

2004
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
    The Lancet. Oncology, 2005, Volume: 6, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms

2005
Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
    International journal of radiation oncology, biology, physics, 2006, Mar-15, Volume: 64, Issue:4

    Topics: Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Treatment Failure

2006
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
    International journal of radiation oncology, biology, physics, 2007, Sep-01, Volume: 69, Issue:1

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Black People; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Disease Progression; Flutamide; Genotype; Goserelin; Humans; Male; Neoplasm Proteins; Practice Guidelines as Topic; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival; White People

2007
Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.
    International journal of radiation oncology, biology, physics, 2008, Feb-01, Volume: 70, Issue:2

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Follow-Up Studies; Gastrointestinal Tract; Goserelin; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Urogenital System

2008
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Prostatic Neoplasms; Survival Rate

2008
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
    European urology, 2008, Volume: 54, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Goserelin; Humans; Male; Middle Aged; Multivariate Analysis; Prostatic Neoplasms; Time Factors

2008
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jun-20, Volume: 26, Issue:18

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors

2008
Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
    International journal of radiation oncology, biology, physics, 2009, Feb-01, Volume: 73, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Canada; Disease-Free Survival; Drug Administration Schedule; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate

2009
Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial.
    Cancer, 2009, Feb-01, Volume: 115, Issue:3

    Topics: Aged; Aged, 80 and over; Biopsy; Canada; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Prostatic Neoplasms; Radiotherapy Dosage; Treatment Outcome

2009
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
    Journal of the National Cancer Institute, 2009, Feb-18, Volume: 101, Issue:4

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Dose Fractionation, Radiation; Endpoint Determination; Flutamide; Follow-Up Studies; Goserelin; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Adjuvant; Research Design; Treatment Failure; Treatment Outcome

2009
Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
    International journal of radiation oncology, biology, physics, 2010, Jan-01, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors

2010
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
    BJU international, 2010, Volume: 105, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Methods; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostatectomy; Prostatic Neoplasms; Treatment Outcome

2010
Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
    The Prostate, 2010, Feb-01, Volume: 70, Issue:2

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Diseases, Metabolic; Flutamide; Goserelin; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Orchiectomy; Parathyroid Hormone; Prospective Studies; Prostatic Neoplasms

2010
Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.
    Journal of biomedicine & biotechnology, 2009, Volume: 2009

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Poland; Prospective Studies; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Factors

2009
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Australia; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Flutamide; Follow-Up Studies; Goserelin; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; New Zealand; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome

2011
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    The New England journal of medicine, 2011, Jul-14, Volume: 365, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Erectile Dysfunction; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Multivariate Analysis; Prostate; Prostatic Neoplasms; Radiotherapy; Radiotherapy Dosage; Risk; Survival Rate

2011
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
    Urology, 2012, Volume: 79, Issue:3

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Goserelin; Humans; Infusions, Subcutaneous; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Prostatic Neoplasms; Treatment Outcome

2012
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Feb-01, Volume: 33, Issue:4

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Time Factors; Tosyl Compounds; Treatment Outcome

2015
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    European urology, 2016, Volume: 69, Issue:2

    Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Follow-Up Studies; Goserelin; Humans; Incidence; Leuprolide; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Time Factors

2016
Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients.
    International urology and nephrology, 2017, Volume: 49, Issue:7

    Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Severity of Illness Index; Sulfonamides; Tamsulosin; Time Factors; Urodynamics

2017
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
    International journal of radiation oncology, biology, physics, 2017, 06-01, Volume: 98, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome

2017
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Canada; Chemoradiotherapy; Dose Fractionation, Radiation; Drug Administration Schedule; Flutamide; Goserelin; Humans; Kallikreins; Leuprolide; Male; Neoplasm Grading; Neoplasm Staging; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; United States

2018

Other Studies

76 other study(ies) available for flutamide and goserelin

ArticleYear
Idiopathic resistance to luteinizing hormone-releasing hormone analogue in a patient with prostatic carcinoma.
    The Journal of urology, 1992, Volume: 148, Issue:5

    Topics: Adenocarcinoma; Aged; Drug Resistance; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone

1992
[A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
    Der Internist, 1992, Volume: 33, Issue:4

    Topics: Aged; Androgen Antagonists; Angina Pectoris; Buserelin; Calcitonin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Hyperhidrosis; Male; Prostatic Neoplasms

1992
Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5 Suppl

    Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Survival Rate

1990
Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report.
    Tumori, 1991, Feb-28, Volume: 77, Issue:1

    Topics: Buserelin; Carcinoma; Flutamide; Goserelin; Humans; Lung Neoplasms; Lymphangitis; Male; Middle Aged; Prostatic Neoplasms

1991
Bone marrow regeneration after hormonal therapy in patients with bone metastases from prostate carcinoma.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1991, Volume: 32, Issue:12

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Bone Marrow; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Organotechnetium Compounds; Prostatic Neoplasms; Radionuclide Imaging; Regeneration

1991
Maximal androgen blockade in prostatic cancer.
    Scandinavian journal of urology and nephrology. Supplementum, 1991, Volume: 138

    Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Orchiectomy; Prostatic Neoplasms

1991
Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
    Clinical endocrinology, 1990, Volume: 32, Issue:3

    Topics: 17-alpha-Hydroxyprogesterone; Aged; Aged, 80 and over; Androgens; Androstenedione; Anilides; Antineoplastic Agents; Buserelin; Dehydroepiandrosterone; Depression, Chemical; Flutamide; Goserelin; Humans; Hydroxyprogesterones; Male; Orchiectomy; Prostatic Neoplasms; Testosterone

1990
EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms

1990
Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    The Journal of urology, 1990, Volume: 144, Issue:4

    Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Luteinizing Hormone; Male; Premedication; Prostatic Neoplasms; Testosterone; Time Factors

1990
Androgens do not regulate the growth hormone response to GHRH in elderly men.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1989, Volume: 21, Issue:12

    Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Testosterone

1989
LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
    Hormone research, 1989, Volume: 32 Suppl 1

    Topics: Androgen Antagonists; Buserelin; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms

1989
The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer.
    International journal of radiation oncology, biology, physics, 1995, Dec-01, Volume: 33, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Prostate; Prostatic Neoplasms; Radiotherapy Dosage; Rectum; Retrospective Studies; Urinary Bladder

1995
Protection of the germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a luteinizing hormone-releasing hormone agonist and antiandrogen therapy.
    Urology, 1995, Volume: 46, Issue:5

    Topics: Animals; Drug Therapy, Combination; Epithelium; Flutamide; Goserelin; Male; Procarbazine; Rats; Rats, Sprague-Dawley; Seminiferous Tubules

1995
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Urology, 1995, Volume: 46, Issue:6

    Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Controlled Clinical Trials as Topic; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds

1995
Hormone therapy prior to radical prostatectomy in patients with clinical stage C prostate cancer.
    The Prostate. Supplement, 1994, Volume: 5

    Topics: Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Treatment Outcome

1994
Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review.
    The Prostate. Supplement, 1994, Volume: 5

    Topics: Aged; Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies

1994
Clinical trials referral resource. Prostate cancer.
    Oncology (Williston Park, N.Y.), 1994, Volume: 8, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lymphatic Metastasis; Male; Middle Aged; Palliative Care; Prostatectomy; Prostatic Neoplasms; Quality of Life

1994
Protection against procarbazine-induced testicular damage by GnRH-agonist and antiandrogen treatment in the rat.
    Endocrinology, 1995, Volume: 136, Issue:8

    Topics: Androgen Antagonists; Animals; Drug Combinations; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Male; Procarbazine; Rats; Spermatogenesis; Testis

1995
[New approaches in the treatment of prostatic cancer].
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 1994, Volume: 46, Issue:3

    Topics: Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms

1994
Prostate cancer.
    Lancet (London, England), 1994, Feb-19, Volume: 343, Issue:8895

    Topics: Adult; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate

1994
[Clinical significance of the local response to prostatic carcinoma during hormonotherapy].
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 1993, Volume: 45, Issue:4

    Topics: Actuarial Analysis; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Organ Size; Prognosis; Prostate; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Testosterone; Treatment Outcome

1993
Advanced prostate cancer. The role of high priced hormone therapy.
    The Medical journal of Australia, 1993, Jul-05, Volume: 159, Issue:1

    Topics: Combined Modality Therapy; Cyproterone Acetate; Diagnosis-Related Groups; Drug Costs; Drug Therapy, Combination; Flutamide; Goserelin; Health Care Costs; Humans; Male; Orchiectomy; Prostatic Neoplasms; Queensland

1993
What is the correct hormonal treatment for prostate cancer?
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:8

    Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Prostatic Neoplasms

1993
Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate.
    European urology, 1995, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms

1995
The use of a removable stent in patients with prostate cancer and obstruction.
    The Journal of urology, 1996, Volume: 155, Issue:6

    Topics: Aged; Antineoplastic Agents, Hormonal; Catheters, Indwelling; Equipment Design; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Stents; Time Factors; Urethra; Urinary Bladder Neck Obstruction; Urinary Catheterization; Urinary Retention

1996
Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer.
    Radiology, 1996, Volume: 199, Issue:2

    Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Clinical Enzyme Tests; Cohort Studies; Combined Modality Therapy; Flutamide; Gastrointestinal Diseases; Goserelin; Humans; Liver Function Tests; Male; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage

1996
Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a).
    Clinical chemistry, 1996, Volume: 42, Issue:8 Pt 1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Apolipoprotein A-I; Body Mass Index; Cholesterol; Cholesterol, HDL; Estradiol; Flutamide; Goserelin; Humans; Lipids; Lipoprotein(a); Male; Middle Aged; Prostatic Neoplasms; Testosterone; Triglycerides

1996
Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
    Acta urologica Belgica, 1996, Volume: 64, Issue:2

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Diethylstilbestrol; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms

1996
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
    Journal of the National Cancer Institute, 1997, Jan-15, Volume: 89, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Flutamide; Gene Expression Regulation, Neoplastic; Genes, p53; Goserelin; Humans; Male; Middle Aged; Mutation; Prognosis; Prostatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis; Tumor Suppressor Protein p53

1997
Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
    International journal of radiation oncology, biology, physics, 1997, Dec-01, Volume: 39, Issue:5

    Topics: Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Case-Control Studies; Combined Modality Therapy; Flutamide; Goserelin; Humans; Leuprolide; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies

1997
The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Cancer, 1998, Oct-15, Volume: 83, Issue:8

    Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Bone Density; Calcium; Carcinoma; Drug Administration Schedule; Etidronic Acid; Evaluation Studies as Topic; Femur Neck; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Longitudinal Studies; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Parathyroid Hormone; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Testosterone; Tomography, X-Ray Computed; Vitamin D

1998
Response of carcinoma of the prostate to withdrawal of flutamide.
    British journal of urology, 1993, Volume: 72, Issue:5 Pt 1

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Goserelin; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms

1993
Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma.
    Human & experimental toxicology, 1999, Volume: 18, Issue:3

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Flutamide; Goserelin; Humans; Liver; Liver Failure, Acute; Liver Function Tests; Male; Middle Aged; Orchiectomy; Prospective Studies; Prostatic Neoplasms

1999
[Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report].
    Hinyokika kiyo. Acta urologica Japonica, 1999, Volume: 45, Issue:8

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Hydronephrosis; Male; Prostatic Neoplasms; Ureteral Obstruction

1999
Numb chin syndrome as the presenting symptom of metastatic prostate carcinoma.
    Urology, 2000, Volume: 55, Issue:2

    Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy; Carcinoma; Chin; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Hypesthesia; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Syndrome

2000
A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
    Japanese journal of clinical oncology, 2000, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Disease Progression; Drug Administration Schedule; Flutamide; Follow-Up Studies; Fractures, Bone; Goserelin; Humans; Leuprolide; Lumbar Vertebrae; Male; Middle Aged; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Survival Rate; Testosterone; Treatment Outcome

2000
[Changes in liver function induced by flutamide in patients with prostate cancer (studies in patients treated with total androgen blockage)].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2000, Volume: 91, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Cholinesterases; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Liver Diseases; Liver Function Tests; Male; Middle Aged; Prostatic Neoplasms

2000
Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Molecular urology, 2000,Fall, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Biopsy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors

2000
Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
    Journal of bone and mineral metabolism, 2001, Volume: 19, Issue:1

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Flutamide; Goserelin; Humans; Male; Osteogenesis; Prostatic Neoplasms; Radionuclide Imaging; ROC Curve

2001
Prostate cancer with multiple lung metastases in a hemodialysis patient.
    International journal of urology : official journal of the Japanese Urological Association, 2000, Volume: 7, Issue:12

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Radiography, Thoracic; Renal Dialysis; Tomography, X-Ray Computed

2000
[Radical prostatectomy with broadened scope of indications - analysis of early experience].
    Khirurgiia, 1999, Volume: 55, Issue:3

    Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms

1999
Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade.
    Journal of endocrinological investigation, 2001, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Appetite; Body Constitution; Body Mass Index; Body Weight; Estradiol; Flutamide; Goserelin; Humans; Insulin; Leptin; Male; Middle Aged; Neuropeptide Y; Prostatic Neoplasms; Regression Analysis; Testosterone

2001
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
    The Prostate, 2001, Jun-15, Volume: 48, Issue:1

    Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Analysis, Statistical; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Research Design; Survival Analysis; Tosyl Compounds; Treatment Outcome

2001
Effect of local heating of rat testes after suppression of spermatogenesis by pretreatment with a GnRH agonist and an anti-androgen.
    Reproduction (Cambridge, England), 2002, Volume: 124, Issue:1

    Topics: Analysis of Variance; Androgen Antagonists; Animals; Epididymis; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hot Temperature; Male; Organ Size; Random Allocation; Rats; Rats, Sprague-Dawley; Sperm Count; Spermatogenesis; Statistics, Nonparametric; Testis

2002
Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.
    The Journal of urology, 2002, Volume: 168, Issue:5

    Topics: Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Feasibility Studies; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms; Survival Rate

2002
The effects of GnRH analogues and antiandrogenes in preventing the gonadotoxic effects of COPP chemotherapy.
    International urology and nephrology, 2001, Volume: 33, Issue:4

    Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Flutamide; Goserelin; Male; Prednisone; Procarbazine; Random Allocation; Rats; Rats, Sprague-Dawley; Vincristine

2001
Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
    The Journal of urology, 2003, Volume: 169, Issue:1

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Black or African American; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; White People

2003
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Prostate cancer and prostatic diseases, 2002, Volume: 5, Issue:4

    Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Biomarkers; Bone Density; Bone Remodeling; Calcium; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Testosterone; Tosyl Compounds

2002
Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoadjuvant Therapy; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds

2003
Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.
    European urology, 2004, Volume: 45, Issue:1

    Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Matched-Pair Analysis; Neoplasm Staging; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds

2004
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
    The American journal of pathology, 2004, Volume: 164, Issue:1

    Topics: Algorithms; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Flutamide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Goserelin; Humans; In Situ Hybridization, Fluorescence; Male; Prostatic Neoplasms

2004
Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade.
    The Journal of urology, 2004, Volume: 171, Issue:4

    Topics: Aged; Androgen Antagonists; Drug Therapy, Combination; Fatal Outcome; Flutamide; Goserelin; Hepatic Encephalopathy; Humans; Male; Prostatic Neoplasms; Tumor Lysis Syndrome

2004
Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
    The Journal of urology, 2004, Volume: 172, Issue:2

    Topics: Aged; Alcohol Drinking; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Comorbidity; Flutamide; Goserelin; Humans; Male; Multivariate Analysis; Nitriles; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Spinal Fractures; Time Factors; Tosyl Compounds; Vitamin D

2004
Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
    Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:3

    Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brachytherapy; Cohort Studies; Flutamide; Gastrointestinal Tract; Goserelin; Hormones; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prognosis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Regression Analysis; Testosterone; Time Factors; Tosyl Compounds; Treatment Outcome; Urogenital System

2005
Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
    Urology, 2005, Volume: 66, Issue:3

    Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gastrointestinal Diseases; Goserelin; Humans; Leuprolide; Male; Male Urogenital Diseases; Nitriles; Prostatic Neoplasms; Radiation Injuries; Time Factors; Tosyl Compounds

2005
Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
    Cancer, 2006, Jan-01, Volume: 106, Issue:1

    Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cost-Benefit Analysis; Flutamide; Goserelin; Humans; Male; Markov Chains; Monte Carlo Method; Neoadjuvant Therapy; Prostatic Neoplasms; Quality-Adjusted Life Years; Radiotherapy, Conformal; Randomized Controlled Trials as Topic

2006
The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Urologia internationalis, 2006, Volume: 77, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Japan; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Tosyl Compounds

2006
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
    Urology, 2006, Volume: 68, Issue:4

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Flutamide; Gene Expression; Gene Expression Profiling; Goserelin; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Predictive Value of Tests; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Treatment Failure

2006
Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:3

    Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy, Needle; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endosonography; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome

2007
The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    The Journal of urology, 2007, Volume: 178, Issue:4 Pt 1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Biomarkers, Tumor; Dihydrotestosterone; Disease Progression; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Orchiectomy; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone

2007
Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
    European urology, 2008, Volume: 54, Issue:4

    Topics: Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms

2008
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30

    Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Multivariate Analysis; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nitriles; Prognosis; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds

2008
Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
    Asian journal of andrology, 2009, Volume: 11, Issue:1

    Topics: Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Dose-Response Relationship, Drug; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome

2009
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    International journal of radiation oncology, biology, physics, 2009, Sep-01, Volume: 75, Issue:1

    Topics: Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Brachytherapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Iodine Radioisotopes; Leuprolide; Male; Nitriles; Palladium; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Tosyl Compounds; Treatment Failure

2009
Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
    Prostate cancer and prostatic diseases, 2010, Volume: 13, Issue:4

    Topics: Aged; Androgen Antagonists; Biomarkers, Tumor; Carcinoma; Epigenesis, Genetic; Flutamide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genotype; Goserelin; Humans; Male; Microarray Analysis; Middle Aged; Prostatic Neoplasms; Prostatic Secretory Proteins; Salivary Proteins and Peptides; Seminal Plasma Proteins

2010
Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
    The Prostate, 2010, Sep-15, Volume: 70, Issue:13

    Topics: Aged; Androgens; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Flutamide; Goserelin; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome

2010
Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
    The Journal of urology, 2010, Volume: 184, Issue:5

    Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms

2010
Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Urologic oncology, 2012, Volume: 30, Issue:5

    Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Flutamide; Goserelin; Human Growth Hormone; Humans; Immunoassay; Insulin-Like Growth Factor I; Logistic Models; Luteinizing Hormone; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone

2012
Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
    International journal of clinical oncology, 2011, Volume: 16, Issue:6

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlormadinone Acetate; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Japan; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome

2011
Mathematical modeling of prostate cancer progression in response to androgen ablation therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Dec-06, Volume: 108, Issue:49

    Topics: Algorithms; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Cells, Cultured; Disease Progression; Drug Administration Schedule; Flutamide; Goserelin; Humans; Male; Models, Biological; Orchiectomy; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Testosterone; Treatment Outcome

2011
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    International journal of radiation oncology, biology, physics, 2012, Aug-01, Volume: 83, Issue:5

    Topics: Analysis of Variance; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Survival; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Seminal Vesicles; Tosyl Compounds

2012
Choice of first-line treatment for metastatic prostate cancer.
    Prescrire international, 2013, Volume: 22, Issue:135

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Estrogens; Flutamide; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome

2013
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
    British journal of cancer, 2017, Oct-10, Volume: 117, Issue:8

    Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; California; Cardiovascular Diseases; Cohort Studies; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Heart Failure; Humans; Imidazolidines; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Nitriles; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Risk Factors; Tosyl Compounds

2017
Status of the Microcirculatory Network as a Factor of Prognosis and Evaluation of Therapeutic Efficiency in Prostate Cancer Treated by High-Intensity Focused Ultrasound in Combination with Androgen Deprivation.
    Bulletin of experimental biology and medicine, 2018, Volume: 165, Issue:5

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antigens, CD34; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Fibrosis; Flutamide; Follow-Up Studies; Goserelin; High-Intensity Focused Ultrasound Ablation; Humans; Male; Microcirculation; Middle Aged; Prognosis; Prostate; Prostatic Neoplasms; Treatment Outcome; Tumor Microenvironment

2018
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
    Cancer, 2019, 04-01, Volume: 125, Issue:7

    Topics: Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Depressive Disorder; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hospitalization; Humans; Imidazolidines; Leuprolide; Male; Mental Health Services; Middle Aged; Nitriles; Oligopeptides; Prostatic Neoplasms; Radiotherapy; Retrospective Studies; Suicide; Tosyl Compounds

2019
Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:2

    Topics: Adverse Drug Reaction Reporting Systems; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Lung Diseases, Interstitial; Male; Prostatic Neoplasms; United States; United States Food and Drug Administration

2023